A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients
- PMID: 3319120
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients
Abstract
Fifty-one patients were enrolled in a double-blind, parallel group, multicentre study conducted to assess short-term efficacy and tolerance of bromocriptine (Parlodel) or L-DOPA/carbidopa (Sinemet) in patients never treated with amantadine, ergot alkaloids or L-DOPA-based drugs. An attempt to use the lowest effective dose was made. The responder rate for each group was approximately 78%; the mean daily dose for responders was 22.5 mg of bromocriptine or 250 mg of L-DOPA/carbidopa. The overall clinical improvement in each group was 62% (bromocriptine) and 55% (L-DOPA/carbidopa) for neurological assessment and 36% (bromocriptine) and 31% (L-DOPA/carbidopa) for functional disability. Comparison between groups did not show any significant difference for both neurological and disability assessments. The most frequent side effect was nausea (L-DOPA, N = 3; bromocriptine, N = 6).
Similar articles
-
Clinical inquiry. Which drugs work best for early Parkinson's disease?J Fam Pract. 2012 Feb;61(2):106-8. J Fam Pract. 2012. PMID: 22312616 Review.
-
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.Prescrire Int. 2005 Apr;14(76):51-4. Prescrire Int. 2005. PMID: 15875340
-
Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.Adv Neurol. 1987;45:535-8. Adv Neurol. 1987. PMID: 3548263 Clinical Trial. No abstract available.
-
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.Neurology. 1989 Nov;39(11 Suppl 2):67-72; discussion 72-3. Neurology. 1989. PMID: 2685652 Clinical Trial.
-
Medical treatment of Parkinson's disease.Compr Ther. 1989 Mar;15(3):53-9. Compr Ther. 1989. PMID: 2650977 Review. No abstract available.
Cited by
-
Evaluation of excess significance bias in animal studies of neurological diseases.PLoS Biol. 2013 Jul;11(7):e1001609. doi: 10.1371/journal.pbio.1001609. Epub 2013 Jul 16. PLoS Biol. 2013. PMID: 23874156 Free PMC article.
-
Update on the use of pramipexole in the treatment of Parkinson's disease.Neuropsychiatr Dis Treat. 2008 Apr;4(2):337-52. doi: 10.2147/ndt.s2325. Neuropsychiatr Dis Treat. 2008. PMID: 18728740 Free PMC article.
-
Bromocriptine versus levodopa in early Parkinson's disease.Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD002258. doi: 10.1002/14651858.CD002258.pub2. Cochrane Database Syst Rev. 2007. PMID: 17943771 Free PMC article. Review.
-
A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):773-5. doi: 10.1136/jnnp.52.6.773. J Neurol Neurosurg Psychiatry. 1989. PMID: 2664089 Free PMC article. Clinical Trial.